Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Drug and Alcohol Review|April 15, 2021
Validation of the French version of the Cannabis Use Disorder Identification Test-Revised and comparison with the Cannabis Abuse Screening Test for screening cannabis use disorder in a psychiatric sampleAmandine Luquiens, Aurélie Berger-Viergat, Agathe Larrieu, et al.Genome Medicine|April 1, 2010
Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetesIain J Gallagher, Camilla Scheele, Pernille Keller, et al.Journal of Science and Medicine in Sport|December 20, 2020
Physical activity, mental health and well-being of adults during initial COVID-19 containment strategies: A multi-country cross-sectional analysisJames Faulkner, Wendy J O'Brien, Bronagh McGrane, et al.Journal of Psychopharmacology (Oxford, England)|June 24, 2023
The New Zealand drug harms ranking study: A multi-criteria decision analysisRose Crossin, Lana Cleland, Chris Wilkins, et al.Plos One|November 14, 2023
Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trialTufail Bashir, Marcus Achison, Simon Adamson, et al.Plos One|October 20, 2023
ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trialChristos Rossios, Tufail Bashir, Marcus Achison, et al.Plos One|August 2, 2024
Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trialAlvin Shrestha, Tufail Bashir, Marcus Achison, et al.Journal of Cachexia, Sarcopenia and Muscle|February 17, 2022
Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial, Marcus Achison, Simon Adamson, et al.The Lancet. Respiratory Medicine|September 8, 2022
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trialHolly R Keir, Merete B Long, Hani Abo-Leyah, et al.Pageof 5